Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

NCT06544733 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

675

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-Infection

Interventions

DRUG: Lepetegravir
DRUG: Lenacapavir pacfosacil
DRUG: Placebo to Match BVY
DRUG: Bictegravir/emtricitabine/tenofovir alafenamide
DRUG: Lepetegravir/Lenacapavir pacfosacil FDC
DRUG: Placebo to Match GS1720/GS-4182 FDC

Sponsor

Gilead Sciences